This cancer-fighting biotech sped from startup to IPO filing in 10 months
September 17, 2018 at 10:03 AM EDT
The company has raised $420 million and its experimental off-the-shelf cell therapy against cancer is in the clinic. But two deaths have been attributed to its headlining drug.
